Jin Woo Kim, Ph.D., Assistant Professor Cancer Biology

Jin Woo Kim, Ph.D.

Assistant Professor, Cancer Biology
Center for Genomics and Personalized Medicine Research
Comprehensive Cancer Center
Center for Cancer Genomics
Center for Genomics and Personalized Medicine Research

Clinical Specialties

Cancer Genetics, Prostate Cancer

Contact Information

Academic: 336-713-7517 | Department: 336-713-7517

Email: jikim@wakehealth.edu

Education & Training

Ph.D., University of Tokyo Faculty of Medicine-Japan , 1999
B.S., , 1991
M.S., , 1995
Fellowship, National Institutes Hlth, 2001
Fellowship, National Institutes Hlth, 2004

Memberships

Am Assn Of Cancer Research

Jin Woo Kim, Ph.D.

Assistant Professor, Cancer Biology Center for Genomics and Personalized Medicine Research
Comprehensive Cancer Center
Center for Cancer Genomics
Center for Genomics and Personalized Medicine Research

Contact Information

Academic: 336-713-7517 | Department: 336-713-7517

Email: jikim@wakehealth.edu

Recent Publications

Feng J, Kim S-T, Liu W, Kim JW, Zhang Z, Zhu Y, Berens M, Sun J, Xu J. An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma. Cancer. 2012;118(1):232-240.

Lu Y, Sun J, Kader AK, Kim S-T, Kim J-W, Liu W, Sun J, Lu D, Feng J, Zhu Y, Jin T, Zhang Z, Dimitrov L, Lowey J, Campbell K, Suh E, Duggan D, Carpten J, Trent JM, Gronberg H, Zheng SL, Isaacs WB, Xu J. Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. Prostate. 2012;72(4):376-385.

Wu M, Shi L, Cimic A, Romero L, Sui G, Lees CJ, Cline JM, Seals DF, Sirintrapun JS, McCoy TP, Liu W, Kim JW, Hawkins GA, Peehl DM, Xu J, Cramer SD. Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res. 2012;72(11):2833-2843.

Kim JW, Kim ST, Turner AR, Young T, Smith S, Liu W, Lindberg J, Egevad L, Gronberg H, Isaacs WB, Xu J. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One. 2012;7(10):e48455.

Jiang W, Wang XW, Unger T, Forgues M, Kim JW, Hussain P, Bowman E, Spillare EA, Lipsky MM, Meck JM, et al. Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer. 2010;127(5):1011-1020.

Kim JW, Cheng Y, Liu W, Li T, Yegnasubramanian S, Zheng SL, Xu J, Isaacs WB, Chang B-L. Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int J Cancer. 2009;124(3):734-738.

Cheng Y, Kim JW, Liu W, Dunn TA, Luo J, Loza MJ, Kim S-T, Zheng SL, Xu J, Chang B-L, et al. Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate. 2009;69(3):327-335.

Sun J, Zheng SL, Li G, Kim S-T, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Liu W, Kim JW, Xu J, Chang B-L, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 2009;69(1):10-15.

Chang B-L, Cramer SD, Sun J, Smith S, Pruett K, Romero LM, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Liu W, Kim JW, Zheng SL, Xu J, et al. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet. 2009;18(7):1368-1375.

Zheng SL, Sun J, Smith S, Pruett K, Kim S-T, Zhu Y, Zhang Z, Hsu F-C, Turner AR, Liu W, Kim JW, Chang B-L, Xu J, et al. Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1815-1820.

Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin L-X, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008;68(5):1451-1461.

Hsu F-C, Lindstrom S, Sun J, Wiklund F, Turner AR, Liu W, Kim JW, Chang B-l, Xu J, Zheng SL, et al. A multigenic approach to evaluating prostate cancer risk in a systematic replication study. Cancer Genet Cytogenet. 2008;183(2):94-98.

Liu W, Chang B, Li T, Dimitrov L, Kim S, Kim JW, Turner AR, Meyers DA, Zheng SL, Xu J, et al. Germline copy number polymorphisms involving larger than 100 kb are uncommon in normal subjects. Prostate. 2007;67(3):227-233.

Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Xu J, et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate. 2007;67(7):692-700.

Liu W, Chang B-L, Li T, Sun J, Turner AR, Dimitrov L, Zhu Y, Sun J, Kim JW, Zheng SL, Xu J, et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer. 2007;46(11):972-980.

Zheng SL, Sun J, Cheng Y, Li G, Hsu F-C, Zhu Y, Chang B-L, Liu W, Kim JW, Turner AR, Xu J, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst. 2007;99(20):1525-1533.

Duggan D, Zheng SL, Dimitrov L, Cheng Y, Li G, Sun J, Chang B-L, Liu W, Kim JW, Bleecker ER, Meyers DA, Xu J, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB21P. J Natl Cancer Inst. 2007;99(24):1836-1844.

Budhu A, Chen Y, Kim JW, Forgues M, Valerie K, Harris CC, Wang XW. Induction of a unique gene expression profile in primary human hepatocytes by hepatitis C virus core, NS3 and NS5A proteins. Carcinogenesis. 2007;28(7):1552-1560.

Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, Yan G, Sun J, Sun J, Adams TS, Turner AR, Kim JW, Meyers DA, Zheng SL, Isaacs WB, Xu J. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer. 2006;45(11):1018-1032.